Langzeittherapie der chronischen Herzinsuffizienz mit Enoximon

Publisher Website
Google Scholar
Abstract
Effect and tolerance of the oral phosphodiesterase inhibitor Enoximone was tested in 14 patients with advanced cardiac fialure (New York Heart Association groups II-IV). During a mean observation period of 40 weeks there were four deaths; one patient became therapy-resistant. The remainder reported sustained clinical improvement. During the observation period there were no changes in heart rate or arterial blood pressure. There were no significant changes in cardiothoracic ratio on the chest X-ray or of the echocardiographically determined left-ventricular diameters. However, there was a rise in shortening fraction from 13.5 .+-. 6.4% to 16.8 .+-. 6.5% after 26 weeks, and to 21.1 .+-. 8.1 after 52 weeks (P < 0.05). The ratio of the systolic time intervals, PEP/LVET, decreased correspondingly from 0.74 .+-. 0.23 to dynamic measurements after one-year treatment revealed an increase in cardiac index from 2.4 .+-. 0.7 to 3.6 .+-. 0.6 l/min .cntdot. m2, and a fall in pulmonary artery wedge pressure from 25.5 .+-. 9.7 to 12.6 .+-. 13.0 mm Hg (P < 0.001). The drug was well tolerated and there were no significant biochemical changes. Long-term ECG monitoring revealed no significant changes in the arrhythmia profiles. Enoximone thus proved to be a successful therapeutic agent in the management of advanced heart failure.